Literature DB >> 12202422

Cyclin A1 and gametogenesis in fertile and infertile patients: a potential new molecular diagnostic marker.

Mark Schrader1, Carsten Müller-Tidow, Stuart Ravnik, Markus Müller, Wolfgang Schulze, Sven Diederichs, Hubert Serve, Kurt Miller.   

Abstract

BACKGROUND: The study aim was to evaluate cyclin A1 mRNA expression levels as a potential molecular diagnostic parameter in the work-up of testicular tissue from fertile versus infertile patients.
METHODS: Cyclin A1 expression was quantified in 55 cryopreserved testicular tissue specimens by fluorescence real-time RT-PCR. A conventional histological work-up was performed concomitantly in all tissue specimens with additional semi-thin sectioning in all cases of non-obstructive azoospermia (n = 12), maturation arrest (n = 17) and Sertoli cell-only syndrome (SCOS; n = 9).
RESULTS: The mean (+/- SD) normalized cyclin A1 expression (N(CyclinA1)) was 3.82 +/- 2.23 relative gene expression (RGE) in tissue specimens with normal spermatogenesis, and 0.625 +/- 0.221 RGE in those with maturation arrest at the level of early spermatids. Only minimal N(CyclinA1) was detected in tissue specimens with spermatogonia only or maturation arrest at the level of primary spermatocytes (0.005 +/- 0.008). Cyclin A1 expression was absent in the majority of SCOS specimens (0.002 +/- 0.002).
CONCLUSIONS: These investigations suggested that cyclin A1 expression is altered in cases of spermatogenic disorders. Moreover, the level of cyclin A1 mRNA expression correlates with gametogenic disorders and seems well suited for a molecular-diagnostic classification supplementing the histopathological evaluation of spermatogenic disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202422     DOI: 10.1093/humrep/17.9.2338

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

Review 1.  Function of the A-type cyclins during gametogenesis and early embryogenesis.

Authors:  Debra J Wolgemuth
Journal:  Results Probl Cell Differ       Date:  2011

2.  Decreased expression of MRE11 and RAD50 in testes from humans with spermatogenic failure.

Authors:  Minhao Hu; Lejun Li; Shuyuan Liu; Yiyun Lou; Liya Wang; Fang Le; Hongping Li; Qijing Wang; Hangying Lou; Ning Wang; Fan Jin
Journal:  J Assist Reprod Genet       Date:  2020-01-25       Impact factor: 3.412

3.  Members of the CDY family have different expression patterns: CDY1 transcripts have the best correlation with complete spermatogenesis.

Authors:  Sandra E Kleiman; Leah Yogev; Ron Hauser; Amnon Botchan; Batia Bar-Shira Maymon; Letizia Schreiber; Gedalia Paz; Haim Yavetz
Journal:  Hum Genet       Date:  2003-09-03       Impact factor: 4.132

4.  Targeted inactivation of testicular nuclear orphan receptor 4 delays and disrupts late meiotic prophase and subsequent meiotic divisions of spermatogenesis.

Authors:  Xiaomin Mu; Yi-Fen Lee; Ning-Chun Liu; Yei-Tsung Chen; Eungseok Kim; Chih-Rong Shyr; Chawnshang Chang
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

5.  A spermatogenesis-related gene expression profile in human spermatozoa and its potential clinical applications.

Authors:  Hui Wang; Zuomin Zhou; Min Xu; Jianmin Li; Junhua Xiao; Zhi-Yang Xu; Jiahao Sha
Journal:  J Mol Med (Berl)       Date:  2004-02-24       Impact factor: 4.599

6.  Epigenetic disruption of the PIWI pathway in human spermatogenic disorders.

Authors:  Holger Heyn; Humberto J Ferreira; Lluís Bassas; Sandra Bonache; Sergi Sayols; Juan Sandoval; Manel Esteller; Sara Larriba
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

Review 7.  A comprehensive review of genetics and genetic testing in azoospermia.

Authors:  Alaa J Hamada; Sandro C Esteves; Ashok Agarwal
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

8.  Maternal cypermethrin exposure during the perinatal period impairs testicular development in C57BL male offspring.

Authors:  Chaobin Huang; Xiangdong Li
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.